Literature DB >> 27277777

Percutaneous radiofrequency ablation for treatment of giant cell tumor of bone guided by real-time US fused with CT.

Qiyu Zhao1, Lifeng Wang2, Fen Chen1, Tian-An Jiang3.   

Abstract

Radiofrequency ablation (RFA) is a well-established technique for the treatment of soft tissue tumors of the liver and kidney that has increasingly been used for both benign and malignant bone tumors, such as giant cell tumor of bone (GCT). Reports in the literature pertaining to RFA for GCT have involved computed tomography (CT)-guided RFA, which presents several drawbacks such as radiation, lack of real-time monitoring, and the fact that it may be time-consuming. We report a case of GCT treated with percutaneous RFA using ultrasound guidance with CT fusion, which offers a simple, real-time guidance solution without radiation.

Entities:  

Keywords:  Computed tomography; Giant cell tumor of bone; Radiofrequency ablation; Ultrasound

Year:  2013        PMID: 27277777     DOI: 10.1007/s10396-013-0482-z

Source DB:  PubMed          Journal:  J Med Ultrason (2001)        ISSN: 1346-4523            Impact factor:   1.314


  21 in total

1.  Laparoscopic and percutaneous ablative techniques in the treatment of renal cell carcinoma.

Authors:  Kent Perry; Amnon Zisman; Allan J Pantuck; Nicolette Janzen; Peter Schulam; Arie S Belldegrun
Journal:  Rev Urol       Date:  2002

2.  Use of radio-frequency ablation for the palliative treatment of sacral chordoma.

Authors:  Nassar Anis; Nohra Chawki; Khoneisser Antoine
Journal:  AJNR Am J Neuroradiol       Date:  2004-10       Impact factor: 3.825

3.  Radiofrequency ablation for non-spinal osteoid osteomas in 557 patients.

Authors:  Eugenio Rimondi; Andreas F Mavrogenis; Giuseppe Rossi; Rosanna Ciminari; Cristina Malaguti; Cristina Tranfaglia; Daniel Vanel; Pietro Ruggieri
Journal:  Eur Radiol       Date:  2011-08-14       Impact factor: 5.315

4.  [CT-guided radiofrequency (RF) ablation of osteoid osteoma: clinical long-term results].

Authors:  D Schmidt; S Clasen; J F Schaefer; H Rempp; S Duda; J Trübenbach; C W König; B Erdtmann; C D Claussen; P L Pereira
Journal:  Rofo       Date:  2011-01-18

5.  Recurrence of curetted and bone-grafted giant-cell tumours with and without adjuvant phenol therapy.

Authors:  K Trieb; P Bitzan; S Lang; M Dominkus; R Kotz
Journal:  Eur J Surg Oncol       Date:  2001-03       Impact factor: 4.424

6.  Ablation of osteoid osteomas with a percutaneously placed electrode: a new procedure.

Authors:  D I Rosenthal; A Alexander; A E Rosenberg; D Springfield
Journal:  Radiology       Date:  1992-04       Impact factor: 11.105

7.  Assessment of health-related quality of life after radiofrequency ablation or laparoscopic surgery for small renal cell carcinoma: a prospective study with medical outcomes Study 36-Item Health Survey (SF-36).

Authors:  Takehisa Onishi; Kouhei Nishikawa; Yoshihiro Hasegawa; Yasushi Yamada; Norihito Soga; Kiminobu Arima; Koichiro Yamakado; Akira Hoshina; Yoshiki Sugimura
Journal:  Jpn J Clin Oncol       Date:  2007-10-17       Impact factor: 3.019

8.  Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study.

Authors:  Tito Livraghi; Luigi Solbiati; M Franca Meloni; G Scott Gazelle; Elkan F Halpern; S Nahum Goldberg
Journal:  Radiology       Date:  2003-02       Impact factor: 11.105

9.  Radiofrequency ablation of chondroblastoma: procedure technique, clinical and MR imaging follow up of four cases.

Authors:  M Christie-Large; N Evans; A M Davies; S L J James
Journal:  Skeletal Radiol       Date:  2008-07-19       Impact factor: 2.199

10.  Chondroblastoma: radiofrequency ablation--alternative to surgical resection in selected cases.

Authors:  Leon D Rybak; Daniel I Rosenthal; James C Wittig
Journal:  Radiology       Date:  2009-03-20       Impact factor: 11.105

View more
  1 in total

1.  Giant cell tumor of bone: A single center study of 115 cases.

Authors:  Niklas Deventer; Tymoteusz Budny; Georg Gosheger; Anna Rachbauer; Jan Puetzler; Jan Christoph Theil; Dmytrii Kovtun; Marieke de Vaal; Nils Deventer
Journal:  J Bone Oncol       Date:  2022-02-17       Impact factor: 4.072

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.